Latest news

Filter by category:

FILTER: ALL CATEGORIESFilter by:

Latest news

25 Oct 2022

CEPI and SK bioscience partner to advance mRNA vaccine technology to build vaccine library, enable rapid response against Disease X
Up to $40 million in funding committed to support development of mRNA-vaccine candidates against Lassa Fever virus and Japanese Encephalitis virus

Read more

Read article

22 Oct 2022

Lassa fever experts gather in Abuja for workshop hosted by CEPI and Nigeria CDC to advance Lassa research
Set up and funded by CEPI, Enable aims to provide a more detailed description of the epidemiology of Lassa fever in West Africa

Read more

12 Oct 2022

As CEPI ramps up vaccine research, a new study warns Lassa fever is set to expand its reach across Africa
Climate change and other environmental factors could cause Lassa fever to spread. CEPI is the leading funder of research into vaccines against the potentially deadly virus.

Read more

10 Oct 2022

Rift Valley fever: What’s next for the climate-driven disease with epidemic potential?
A Q+A with CEPI Vaccine R&D Project Leader, Mike Whelan, discussing the characteristics of the disease and CEPI's new call with the European Union to advance Rift Valley fever vaccines.

Read more

06 Oct 2022

CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccine
The Avacc 101 vaccine candidate will be designed to provide broad protection against SARS-CoV-1, SAR-CoV-2, and MERS-CoV

Read more

16 Sep 2022

Rift Valley fever vaccines to advance with new $50 million CEPI and EU funding call
Up to USD 50m (EUR 50m) will be provided to vaccine projects, with support from the European Union’s Horizon Europe programme.

Read more

08 Sep 2022

The Race to Future-Proof Coronavirus Vaccines
To help humanity get ahead, we need vaccines that provide broad protection against new variants of COVID-19 as well as future coronavirus threats.

Read more

31 Aug 2022

CEPI partner IAVI announces first vaccinations at Liberia site in Phase I clinical trial of Lassa Fever vaccine candidate
The trial is designed to evaluate the candidate’s safety, tolerability, and immunogenicity.

Read more

Read article

28 Jul 2022

CEPI, UK MHRA, and UK Health Security Agency to advance key tools for Monkeypox vaccine research
Up to US$375k will be made available by CEPI for the development of a Monkeypox antibody standard and assays.

Read more

26 Jul 2022

CEPI statement: CEO welcomes White House Summit on the Future of COVID-19 Vaccines
Dr Richard Hatchett calls for heightened investment to develop the next generation of globally accessible COVID-19 vaccines

Read more

19 Jul 2022

Q+A: How CEPI-funded research is supporting the COVID-19 vaccine rollout
CEPI’s Director of Clinical Development, Jakob Cramer, discusses the research CEPI is supporting to inform global COVID-19 vaccination strategies.

Read more

©2022 CEPI. All rights reserved